Creatine vs NAD+: Comparing the Indexed Record
Creatine and NAD+ are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Compound profiles
Creatine in the indexed record
Creatine returns 68,049 indexed records on PubMed, an extensive record, alongside 2,608 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Nutr Neurosci, Nutrients, Sports Health, spanning 2018–2023.
- Effects of Creatine Supplementation on Brain Function and Health — Nutrients, 2022. PMID: 35267907
- Creatine in Health and Disease — Nutrients, 2021. PMID: 33572884
- Creatine Use in Sports — Sports Health, 2018. PMID: 29059531
- Creatine and multiple sclerosis — Nutr Neurosci, 2022. PMID: 32912105
NAD+ in the indexed record
Searching NAD+ against the PubMed index returns 76,583 records, an extensive evidence base, alongside 749 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
How the literature differs
The indexed record is not symmetrical between these two compounds. NAD+ carries 8,534 more indexed records than Creatine, which means published methodology, characterisation data and replication attempts are more readily located for NAD+. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (2,608 vs 749) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Creatine | NAD+ |
|---|---|---|
| PubMed indexed records | 68,049 | 76,583 |
| Registered studies (ClinicalTrials.gov) | 2,608 | 749 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Creatine and NAD+ sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Creatine describes conditions validated for Creatine: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to NAD+ without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Selecting between them for a study design
Creatine and NAD+ are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (NAD+) generally offers more methodological precedent.
Frequently asked questions
Which of Creatine or NAD+ has more published research?
NAD+, with 76,583 indexed PubMed records against 68,049.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are Creatine and NAD+ the same compound?
No. They are structurally distinct research compounds with separate literature records — 68,049 indexed records for Creatine and 76,583 for NAD+.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.